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Summary To evaluate the safety and effectiveness of a humanized respiratory
syncytial virus (RSV) monoclonal antibody (palivizumab) to control an
outbreak of RSV in a neonatal intensive care unit (NICU), we retrospectively
analysed two RSV outbreaks. Between 11 November 1998 and 18 March 1999,
two separate RSV outbreaks occurred in a large (26 beds) NICU. All procedures
for preventing nosocomial spread of RSV (including the use of palivizumab in
the second outbreak) were retrospectively analysed. The cumulative
incidence (CI), secondary attack rate (SAR) and risk ratio of infection were
determined before and after the use of palivizumab for all patients and for
those with gestational age below and above 32 weeks in the NICU during the
second outbreak. Standard infection control measures were effective in the
first outbreak (three cases). In the second outbreak, after three index cases,
five additional infants were newly RSV-infected within one month. Three
infants had RSV pneumonia and required mechanical ventilation; one infant
died. Standard infection control procedures were initiated from the beginning
of this outbreak. Palivizumab was given to all infants in the NICU after the
fifth case was identified. CI was 2.4% in the first 15 days and 10.5% in the
second, and SAR was 2.9‰ in the first 15 days and 14.1‰ in the second, both
dropping to zero after the administration of palivizumab. The risk ratio of
infection was 4.65 times higher in infants under 32 weeks gestational age.
After the use of palivizumab, there were no additional identified cases. In
addition to careful infection control procedures, the use of palivizumab might
have contributed to arresting the outbreak of RSV infection in the NICU,
suggesting that it could be an additional resource in the control of severe
nosocomial RSV outbreaks.
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Introduction
Respiratory syncytial virus (RSV) is the most
common aetiologic agent identified in lower respir-
atory tract infections in infants. Risk factors for
severe RSV infection include prematurity, chronic
lung disease, immunodeficiency and congenital
heart disease.1,2 Premature infants are a particular
risk group because of their small airways, immature
immunological system, and low levels of maternally
acquired RSV-specific antibodies.3
RSV outbreaks in neonatal units have been well
described. Hospital staff are thought to be the main
vector, transmitting the virus via contaminated
hands. A number of studies have suggested that
handwashing after patient contact, use of gowns
and gloves, and cohort nursing are usually effective
preventive strategies against nosocomial spread of
RSV.4,5
Palivizumab (Synagisw—MedImmune Inc.,
Gaithersburg, MD, USA) is a humanized monoclonal
antibody directed against the F glycoprotein of RSV,
and was recently approved for the prophylaxis of
RSV disease in high-risk infants.6 –8 If a RSV outbreak
is documented in a high-risk unit, primary emphasis
should be placed on proper infection control
procedures. In uncontrolled outbreaks, however,
the effectiveness of prophylaxis with palivizumab
has not been evaluated.6–11
The aims of this study were to evaluate the
procedures to control the infection and the safety
and effectiveness of humanized RSV monoclonal
antibodies (palivizumab) during an outbreak of RSV
in a large neonatal intensive care unit (NICU).
Methods
The intensive care units of the Department of
Paediatrics (Hospital Fernando Fonseca, Lisbon) are
contiguous: the NICU contains 26 beds (six intensive
and 20 special care units) and the paediatric
intensive care unit (PICU) contains 11 beds. These
rooms share some clinical staff. Altogether some
800 children are admitted per year. Between
November 1998 and March 1999, two RSV outbreaks
occurred in the NICU. All cases of RSV infection
during this period and the procedures instituted to
control the spread of the virus in both outbreaks
were retrospectively analysed.
Infection was diagnosed by membrane-bound
enzyme immunoassay for virus antigen from naso-
pharyngeal washings (Directigene—RSV test, Bec-
ton Dickinson Microbiology Systems, USA). After the
index cases (first cases identified), all infants were
screened for RSV from nasopharyngeal washings.
Those with upper respiratory symptoms were
screened every two days until a negative result
was reported.
In the setting of both RSV outbreaks, standard
infection control procedures, including handwash-
ing, use of gowns and gloves, and cohort nursing,
were started immediately. In the setting of the
second RSV outbreak, after failure of standard
infection control procedures, palivizumab was also
used. Palivizumab was administered to all the
babies in the unit at a dose of 15 mg/kg intramus-
cular and repeated one month later.
The cumulative incidence (CI; proportion of
children at risk that became ill), secondary attack
rate (SAR; relationship between the number of
newly infected patients in each period and the total
sum of days at risk) and risk ratio of infection were
determined before and after the initiation of
palivizumab for all the patients; these were also
calculated separately for infants with gestational
age below and above 32 weeks (WGA).
Results
In the first outbreak (November/December 1998),
three cases of RSV infection (two in the NICU and
one in the PICU) were identified simultaneously.
Standard infection control procedures were rigor-
ously employed and included handwashing, use of
gowns and gloves, and cohort nursing; these
measures were effective in halting the further
spread of infection. After these, there were no
more identified cases in the NICU.
In February 1999, a second RSV outbreak
occurred in the NICU. There were three index
cases (two infants in the PICU admitted from the
outside and one in the NICU identified at the same
time as the other two). The index cases were
epidemiologically responsible for starting the out-
break, which occurred only in the NICU. Standard
infection control procedures were once again
rigorously instituted; despite this, however, five
additional infants were infected in one month in the
NICU. Four of these five RSV cases were preterm
under 32 WGA. Three developed pneumonia and
required mechanical ventilation; one infant died.
The overall fatality rate was 12.5%.
On 3 March 1999, it was decided to begin
immunoprophylaxis with palivizumab; this was
administered to all infants in the NICU (a total of
19). CI and SAR were determined for four periods of
15 days (the sum of average expected days of virus
shedding and of incubation period), starting from
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the index case’s identification’. The number of
patients at risk (in the NICU) were 41, 38, 27 and 39
in each 15-day period [Figure 1(a)]. CI was 2.4% in
the first 15 days and 10.5% in the second, dropping
to zero after the administration of palivizumab
[Figure 1(a)]. RSV infection rates rose significantly
in infants less than 32 WGA. These babies had a 4.65
times higher risk of becoming infected than infants
above 32 WGA (CL95 0.53 , relative risk , 40.2)
[Figure 1(b)].
SAR was 2.9‰ in the first 15-day and 14.1‰ in
the second 15-day [Figure 2(a)]. Rates of infection
increased with increasing levels of exposure to RSV,
as measured by the days that susceptible patients
were exposed to patients shedding the virus.
After the day of identification of the index cases
and over two additional months, a total of 126
infants were admitted to the NICU. After instituting
palivizumab, there were no additional RSV-positive
cases identified. Palivizumab was well tolerated
and no adverse events were reported. The global
cost of palivizumab administration was 7619 euros
(401 euros per patient).
Discussion
RSV is highly contagious, spreading rapidly among
infants, families and those on paediatric wards. The
virus survives for up to 7 h on countertops, gloves,
paper tissues and clothes, and for 30 min on skin.12
The initiation of rigorous infection control pro-
cedures (handwashing, gowns and gloves, and
cohort nursing) was effective in the first RSV
nosocomial outbreak identified in the unit (Novem-
ber/December 1999). With the second nosocomial
outbreak, however, these infection control policies
were not effective in preventing further cases of
RSV illness with significant morbidity. Palivizumab
was therefore initiated for all infants in our NICU.
There were no additional RSV cases and palivizumab
was safe and well tolerated.
It is known that infected children will continue to
shed the virus for up to two to three weeks.12 This
increases the risk of infection in a busy NICU. In this
study, SAR was 2.9‰ in the first 15 days and 14.1‰
in the second. These observations were a clear sign
that standard infection control measures were not
Figure 1 The CI (%) during the outbreak picked through
the third and fourth weeks (a); children with gestational
age less than 32 weeks had a much higher CI (RR ¼ 4.65)
(b). (A) ,32 weeks; (B) .32 weeks.
Figure 2 The SAR during the outbreak picked through
the third and fourth weeks (a); children with gestational
age less than 32 weeks had a much higher SAR
(RR ¼ 2.37%) (b) (B) ,32 weeks; (A) .32 weeks.
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successful and that additional intervention was
necessary. The cost for not initiating a new
approach would be prolonged closure of the NICU
to new admissions and potentially additional severe
RSV cases and fatalities. Closing the NICU for two
months would further overload the other four NICUs
in Lisbon close to collapse.
It was observed in the NICU that babies below 32
WGA had a 4.65 times higher risk of becoming
seriously ill than those above 32 WGA, which is
consistent with what was expected.1,3,8,13 Three
babies had severe RSV illness (one death) and all
were under 32 WGA.
Palivizumab is a humanized monoclonal antibody
that specifically inhibits an epitope at the A
antigenic site of the F protein of both RSV subtypes
A and B. Antibody binding to the F protein has two
effects. First, it prevents cellular infection by
preventing the viral membrane from fusing with
the respiratory epithelial cell membrane. Second, it
prevents cell-to-cell spread of the virus, which in
turn prevents the formation of syncytia and release
of inflammatory mediators in the lung.10 These
properties provide the rationale for its clinical use.
The Food and Drug Administration approved
palivizumab use for RSV disease prophylaxis
among high-risk infants. The American Academy
of Pediatrics and the European Commission for
Proprietary Medicinal Products recently published
recommendations for its use.6,10 Palivizumab pro-
phylaxis is considered for infants and children with
chronic lung disease (CLD) younger than two years;
infants born between 29 and 32 WGA, without CLD,
up to six months of age; infants born less than 29
WGA, without CLD, up to 12 months of age, at the
start of the RSV season; and infants born between
32 and 35 WGA, without CLD, who have additional
risk factors. These recommendations also stress
that use of palivizumab in nosocomial NICU out-
breaks needs to be studied before specific rec-
ommendations in this area can be made.6–11,14
Cox et al.15 reported a similar experience where
palivizumab was also used to control an RSV
outbreak in a special care baby unit. The need
for, and efficacy of, prophylaxis in the setting
of an RSV outbreak in an NICU needs further
investigation.
In addition to meticulous infection control
procedures, the use of palivizumab might have
contributed to stop an uncontrolled RSV nosocomial
outbreak in a large NICU. This experience suggests
that palivizumab may be an additional resource for
the containment of severe RSV outbreaks. Never-
theless, this is a costly intervention (400 euros per
patient). It must be remembered that for high-risk
and low-risk patients alike, this prophylaxis does
not replace the simple and inexpensive preventive
measure of handwashing. Further studies should be
undertaken to assess the role of palivizumab in
nosocomial RSV settings.
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